Tyler Zeronda
Director of Finance/CFO bij VYNE THERAPEUTICS INC.
Vermogen: 404 451 $ op 31-03-2024
Profiel
Tyler Zeronda is currently the Chief Financial Officer & Treasurer at VYNE Therapeutics, Inc. He previously worked as the Director-Finance at Aerie Pharmaceuticals, Inc. Mr. Zeronda holds a graduate degree from the University of Virginia and an undergraduate degree from Lafayette College.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
VYNE THERAPEUTICS INC
0.93% | 01-04-2024 | 131 743 ( 0.93% ) | 404 451 $ | 31-03-2024 |
Actieve functies van Tyler Zeronda
| Bedrijven | Functie | Begin |
|---|---|---|
| VYNE THERAPEUTICS INC. | Director of Finance/CFO | 18-06-2021 |
Eerdere bekende functies van Tyler Zeronda
| Bedrijven | Functie | Einde |
|---|---|---|
| AERIE PHARMACEUTICALS, INC. | Director of Finance/CFO | - |
Opleiding van Tyler Zeronda
| University of Virginia | Graduate Degree |
| Lafayette College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| VYNE THERAPEUTICS INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Aerie Pharmaceuticals, Inc.
 Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
